D’Alessandris and colleagues216 showed a 100% radiographic response rate with erlotinib plus bevacizumab treatment in recurrent glioblastoma patients pre-screened for high EGFR and VEGF expression. This evidence concerns the gene VEGFA and glioblastoma.